Eagle Asset Management Inc Bluebird Bio, Inc. Transaction History

Eagle Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 07, 2020	SELL	$46.96 - $61.67 $13.4 Million - $17.6 Million	-284,925 Closed	0 $0
Q3 2019 Nov 04, 2019	SELL	$59.47 - $93.1 $4,460 - $6,982	-75 Reduced 0.03%	284,925 $26.2 Million
Q2 2019 Aug 05, 2019	BUY	$75.84 - $105.21 $188,310 - $261,236	2,483 Added 0.88%	285,000 $36.3 Million
Q1 2019 May 01, 2019	BUY	$64.44 - $104.11 $226,699 - $366,258	3,518 Added 1.26%	282,517 $44.4 Million
Q4 2018 Feb 11, 2019	BUY	$59.1 - $93.26 $2.22 Million - $3.51 Million	37,602 Added 15.58%	278,999 $27.7 Million
Q3 2018 Nov 08, 2018	BUY	$88.86 - $117.49 $5.69 Million - $7.52 Million	64,024 Added 36.1%	241,397 $35.2 Million
Q2 2018 Aug 07, 2018	SELL	$99.64 - $127.59 $5.23 Million - $6.7 Million	-52,528 Reduced 22.85%	177,373 $27.8 Million
Q1 2018 May 09, 2018	SELL	$105.8 - $150.94 $240,906 - $343,690	-2,277 Reduced 0.98%	229,901 $39.3 Million
Q4 2017 Feb 09, 2018	SELL	$81.25 - $130.7 $267,150 - $429,741	-3,288 Reduced 1.4%	232,178 $41.6 Million
Q3 2017 Nov 09, 2017	BUY	$57.74 - $91.42 $13.6 Million - $21.5 Million	235,466	235,466 $29.5 Million

149

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $652M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.